The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Leu-leu-ome     methyl (2S)-2-[[(2S)-2...

Synonyms: AC1Q5JSS, CTK8D8855, AR-1J5867, LS-172757, AC1L3G28, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Leucyl-leucine-methyl ester


High impact information on Leucyl-leucine-methyl ester

  • In this regard, Leu-Leu-OMe was found to be incorporated by lymphocytes and monocytes via a saturable facilitated transport mechanism with characteristics distinct from previously characterized mammalian dipeptide transport processes [1].
  • However, some NK nontoxic DPPI substrates were found to be comparable with Leu-Leu-OMe in avidity for this transport process [1].
  • L-leucine methyl ester (Leu-OMe), Leu-Leu-OMe, Phe-OMe, and Glu-(OMe)2 are toxic to mononuclear phagocytes (M phi) and neutrophils [2].
  • Depletion of DPPI-enriched cells by treatment with Leu-Leu-OMe resulted in loss of cytolytic effector function from each CTL population [3].
  • Thus, killing of cytotoxic lymphocytes and myeloid cells by Leu-Leu-OMe appears to be dependent on generation of metabolites with membranolytic properties, but cell death induced by this process does not involve simple lysis of the plasma membrane [4].

Chemical compound and disease context of Leucyl-leucine-methyl ester

  • Previous studies have demonstrated that the selective toxicity of leucyl-leucine methyl ester (Leu-Leu-OMe) for cytotoxic lymphocytes and myeloid cells is dependent on intracellular conversion to membranolytic metabolites by the acyl transferase activity of the granule enzyme dipeptidyl peptidase I (DPPI) that is enriched in these cells [4].

Anatomical context of Leucyl-leucine-methyl ester

  • Preincubation with Zn2+, a known inhibitor of endonuclease activity prevented Leu-Leu-OMe-induced 51Cr or [3H]TdR release from these cell lines, but had no effect on antibody + C or Phe-OMe-induced 51Cr release [4].
  • Zn2+ also prevented Leu-Leu-OMe-mediated killing of normal human CD16+ NK cells [4].
  • When human U937, HL60, or THP-1 myeloid tumor cell lines or murine CTLL-2 cells were treated with Leu-Leu-OMe, early release of both cytosolic 51Cr and soluble [3H]TdR labeled DNA fragments was observed, whereas antibody + C treatment of these cells caused only 51Cr release [4].
  • The two major gamma delta T cell subsets V gamma 9+V delta 2+ and V gamma 9-V delta 1+ were equally susceptible to Leu-OMe and Leu-Leu-OMe treatment [5].
  • Porcine polymorphonuclear cells (PMN) and murine macrophages (M phi) were treated in vitro with Leu-OMe or Leu-Leu-OMe (1.5-5.0 mM) for various periods of time [6].

Analytical, diagnostic and therapeutic context of Leucyl-leucine-methyl ester

  • Six of seven dogs conditioned with 920 cGy total-body irradiation engrafted successfully after receiving autologous marrow that was incubated with Leu-Leu-OMe prior to infusion [7].
  • These cumulative results indicate that incubation with Leu-Leu-OMe is a feasible method to deplete canine marrows of alloreactive and cytotoxic T cells prior to transplantation [7].


  1. The action of leucyl-leucine methyl ester on cytotoxic lymphocytes requires uptake by a novel dipeptide-specific facilitated transport system and dipeptidyl peptidase I-mediated conversion to membranolytic products. Thiele, D.L., Lipsky, P.E. J. Exp. Med. (1990) [Pubmed]
  2. Spectrum of toxicities of amino acid methyl esters for myeloid cells is determined by distinct metabolic pathways. Thiele, D.L., Lipsky, P.E. Blood (1992) [Pubmed]
  3. Dipeptidyl peptidase I is enriched in granules of in vitro- and in vivo-activated cytotoxic T lymphocytes. Brown, G.R., McGuire, M.J., Thiele, D.L. J. Immunol. (1993) [Pubmed]
  4. Apoptosis is induced in cells with cytolytic potential by L-leucyl-L-leucine methyl ester. Thiele, D.L., Lipsky, P.E. J. Immunol. (1992) [Pubmed]
  5. Human peripheral blood gamma delta T cells are uniformly sensitive to destruction by the lysosomotropic agents leucine methyl ester and leucyl leucine methyl ester. Pechhold, K., Kabelitz, D. Eur. J. Immunol. (1993) [Pubmed]
  6. Formation of leucyl-leucine-O-methylester in leucine-O-methylester treated cells. Solymossy, M., Antoni, F., Csuka, I., Temesi, A., Bánfalvi, G. Acta physiologica Hungarica. (1994) [Pubmed]
  7. L-leucyl-L-leucine methyl ester treatment of canine marrow and peripheral blood cells. Inhibition of proliferative responses with maintenance of the capacity for autologous marrow engraftment. Raff, R.F., Severns, E., Storb, R., Martin, P., Graham, T., Sandmaier, B., Schuening, F., Sale, G., Appelbaum, F.R. Transplantation (1988) [Pubmed]
WikiGenes - Universities